YOLFTbeta
Shine-On BioMedical Co.,Ltd.

Shine-On BioMedical Co.,Ltd.

6926 · TWO · Healthcare / Biotechnology

59.50TWD-0.40 (-0.67%)

Price History

Full chart

Market Stats

Previous Close59.90
Open60.00
Day Range57.00 – 60.00
52-Week Range59.90 – 73.60
Volume15.03K
Market Cap3.35B
P/E (TTM)0.00
Forward P/E0.00
EPS-3.64
Dividend Yield0.00%
Beta-0.14
50-Day Avg63.45
200-Day Avg65.76

About

Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody. Shine-On BioMedical Co.,Ltd. was founded in 2011 and is based in Taichung, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Hongzhe Jiang
  • Employees22
  • Headquarters10F, No. 573, Taichung, Taiwan, 407569, Taiwan
  • Websitehttps://www.shineon-bio.com

Leadership

  • Mr. Hongzhe JiangGeneral Manager

Financials

Income Statement

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue009.52M030.00M
Growth (%)----100.00%-
Cost of Revenue638.00K1.63M2.86M2.19M0
Gross Profit-638.00K-1.63M6.67M-2.19M30.00M
Gross Margin--70.00%-100.00%
Operating Expense7.99M20.17M69.35M133.88M155.50M
Operating Income-8.62M-21.79M-62.68M-136.07M-125.50M
Operating Margin---658.16%--418.33%
EBITDA-7.78M-20.17M-33.01M-116.37M-108.33M
EBITDA Margin---346.56%--361.08%
Net Income-8.43M-19.54M-37.16M-118.89M-110.28M
Net Income Margin---390.22%--367.62%
R&D6.00M6.90M54.24M119.28M137.84M
R&D as % of Total Revenue--569.52%-459.46%
Interest Expense16.00K26.00K13.00K26.00K27.00K
Interest Expense % of Total Revenue--0.14%-0.09%

Balance Sheet

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets911.82M1.18B1.16B1.06B950.94M
Total Liabilities4.25M4.14M23.25M42.21M43.66M
Total Equity907.57M1.17B1.14B1.02B907.28M
Cash824.98M373.16M102.02M44.66M49.17M
Total Debt2.67M1.52M538.00K2.60M-
Net Debt-822.32M-371.64M-101.49M-42.06M-

Cash Flow

Currency: TWD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.34M-21.66M-26.88M-91.45M-114.75M
Investing Cash Flow-84.24M-714.78M-243.26M35.36M-
Financing Cash Flow915.57M284.61M-991.00K-1.28M-
Capital Expenditure2.96M2.78M662.00K608.00K1.04M
Free Cash Flow-9.30M-24.43M-27.54M-92.06M-115.78M
FCF to OCF146.59%112.82%102.46%100.66%100.91%

Key Statistics & Ratios

Market Cap3.35B
Enterprise Value2.36B
Trailing P/E0.00
Forward P/E0.00
Price / Sales66.12
Price / Book4.01
EPS-3.64
Book Value15.89
Revenue (TTM)50.62M
Gross Profit (TTM)50.62M
EBITDA-193.77M
Profit Margin0.00%
Operating Margin-592.05%
Return on Equity-20.60%
Return on Assets-13.37%
Shares Outstanding49.80M
Shares Float22.22M
Beta-0.14
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%